Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
BioMarin Pharmaceutical Inc Market Cap
The BioMarin Pharmaceutical Inc (BMRN) share price is expected to increase by 48.83% over the next year. This is based on calculating the average 12-month share price estimate provided by 24 stock analysts who have covered BMRN. Price targets range from $72 at the low end to $139 at the high end. The current analyst consensus for BMRN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 24 Wall Street analysts have assigned BMRN 19 buy ratings, 5 hold ratings, and 0 sell ratings. This means that analysts expect BioMarin Pharmaceutical Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BMRN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of BMRN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Luca Issi RBC Capital | Sector Perform | $80 | Maintains | Oct 4, 2024 |
| Gena Wang Barclays | Overweight | $86 | Maintains | Oct 4, 2024 |
| William Pickering Bernstein | Outperform | $90 | Maintains | Sep 17, 2024 |
| Paul Matteis Stifel | Buy | $87 | Maintains | Sep 17, 2024 |
| Joon Lee Truist Securities | Buy | $90 | Maintains | Sep 17, 2024 |
| George Farmer Scotiabank | Sector Perform | $78 | Maintains | Sep 17, 2024 |
| Luca Issi RBC Capital | Sector Perform | $85 | Maintains | Sep 17, 2024 |
| Geoff Meacham B of A Securities | Buy | $115 | Maintains | Sep 17, 2024 |
| Mohit Bansal Wells Fargo | Overweight | $90 | Maintains | Sep 17, 2024 |
| Whitney Ijem Canaccord Genuity | Hold | $93 | Maintains | Sep 13, 2024 |
| Olivia Brayer Cantor Fitzgerald | Overweight | $110 | Reiterates | Sep 9, 2024 |
| Joon Lee Truist Securities | Buy | $118 | Maintains | Sep 5, 2024 |
| George Farmer Scotiabank | Sector Perform | $95 | Maintains | Sep 5, 2024 |
| Christopher Raymond Piper Sandler | Overweight | $122 | Maintains | Sep 5, 2024 |
| Jessica Fye JP Morgan | Overweight | $120 | Maintains | Sep 5, 2024 |
| Luca Issi RBC Capital | Sector Perform | $100 | Reiterates | Sep 5, 2024 |
| Christopher Raymond Piper Sandler | Overweight | $107 | Maintains | Aug 27, 2024 |
| Paul Matteis Stifel | Buy | $115 | Maintains | Aug 21, 2024 |
| William Pickering Bernstein | Outperform | $110 | Upgrade | Aug 20, 2024 |
| Paul Matteis Stifel | Buy | $112 | Maintains | Aug 6, 2024 |
When did it IPO
1999
Staff Count
3,401
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Alexander Hardy
Market Cap
$13.23B
In 2023, BMRN generated $2.42B in revenue, which was a increase of 15.42% from the previous year. This can be seen as a signal that BMRN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 01 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - BioMarin (BMRN) is currently oversold, suggesting potential for a trend reversal, supported by analysts raising earnings estimates.
Why It Matters - BioMarin (BMRN) may see a price rebound due to oversold conditions and increased earnings estimates, signaling potential growth and recovery in stock performance.
Tue, 01 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - BioMarin (BMRN) shows strong financial growth and is expected to outperform the market, indicating a positive outlook for investors.
Why It Matters - BioMarin's above-average growth indicates strong financial health, suggesting potential for increased stock value and returns, making it an attractive option in the market.
Thu, 03 Oct 2024
Sentiment - POSITIVE
Source - MarketBeat
Summary - The Relative Strength Index (RSI) is a widely used technical indicator that helps investors identify potential bargain stocks.
Why It Matters - The RSI helps identify undervalued stocks, signaling potential buying opportunities, which can lead to gains as prices adjust to reflect their true value.
Tue, 01 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - BioMarin Pharmaceutical (BMRN) and Myriad Genetics (MYGN) are both notable stocks in the Medical - Biomedical and Genetics sector, appealing to investors seeking undervalued opportunities.
Why It Matters - The comparison between BioMarin Pharmaceutical and Myriad Genetics highlights potential investment opportunities in the undervalued segment of the biomedical sector, influencing portfolio decisions.
Mon, 30 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Style Scores help investors identify top-rated stocks aligned with their investing style, providing a useful tool for stock selection.
Why It Matters - The Zacks Style Scores provide a streamlined method to identify high-potential stocks, aiding investors in making informed decisions aligned with their strategies.
Wed, 25 Sep 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Ascendis Pharma A/S (ASND) announced topline trial data involving 84 children with achondroplasia, a genetic disorder causing dwarfism, last week.
Why It Matters - Ascendis Pharma's trial results for achondroplasia could impact stock performance, signaling potential market opportunities or risks based on treatment efficacy and future approvals.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
